Malarone

Atovaquone, the active ingredient in Malarone, is an antimalarial presented as a 250 mg atovaquone / 100 mg proguanil hydrochloride tablet for oral use. It treats and prevents malaria infection in travelers and patients at risk.

GNH USA supplies Malarone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Malarone (atovaquone/proguanil) is used in the antimalarial therapeutic class to prevent and treat malaria caused by Plasmodium species.

- Prevention of malaria: provides prophylactic protection for travelers to endemic regions. - Treatment of acute uncomplicated malaria (Plasmodium falciparum): achieves parasite clearance in patients with non‑resistant infection. - Treatment of acute uncomplicated malaria (Plasmodium vivax): achieves parasite clearance in patients with non‑resistant infection.

Common side effects are generally mild and reversible.

Common Side Effects: - Nausea: occasional upset stomach. - Headache: mild to moderate intensity. - Abdominal pain: cramping or discomfort. - Diarrhoea: loose stools.

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome): requires immediate medical attention. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Hemolysis in patients with G6PD deficiency: watch for dark urine and fatigue. - Severe neutropenia: increased infection risk. - Anaphylaxis or hypersensitivity: rapid onset of breathing difficulty or swelling.

Malarone requires careful consideration of patient‑specific factors before use.

- Pregnancy: safety not established; use only if benefits outweigh risks. - Breastfeeding: unknown; consider potential exposure to infant. - Renal impairment: dose adjustment may be needed in severe cases. - Drug resistance: ensure adherence to regimen to avoid resistance development. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep in original pack, protect from moisture and light.

Malarone can interact with several medicines; categorisation helps guide monitoring.

Major Interactions (Avoid): - Rifampin: markedly reduces atovaquone plasma concentrations. - Cimetidine: may increase atovaquone exposure. - Protease inhibitor antiretrovirals: can alter drug metabolism.

Moderate Interactions (Monitor Closely): - Antacids containing aluminium or magnesium: may decrease atovaquone absorption. - Warfarin: proguanil may potentiate anticoagulant effect; monitor INR. - Macrolide antibiotics: possible additive QT‑prolongation; observe cardiac rhythm.